NHS England will not routinely commission surgery for pectus deformity in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

NHS England will commission everolimus as an add on treatment of people aged 2 and above who have tuberous sclerosis related seizures in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

NHS England will commission metreleptin treatment for patients with congenital leptin deficiency in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

NHS England will commission trientine for Wilson disease in all ages in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

NHS England will commission stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) for palliative treatment of patients with primary non-germ cell pineal region tumours in accordance with the criteria set out in this document.

This service specification covers the provision of hyperbaric oxygen treatment services (adults and children).

NHS England will not routinely commission clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation in accordance with the criteria outlined in this document.

This policy document outlines the arrangements for funding of the use of cobicistat as a booster in treatment of HIV infection (all ages).

This service specification covers the provision of environmental controls which is one aspect of the specialist services to support patients with complex physical disabilities (excluding wheelchair services).

This policy document outlines the commissioning arrangements for hyperbaric oxygen therapy for soft tissue radiation damage in patients with a history of pelvic irradiation for malignant disease (all ages)